Skip to content
PeptideAgent

GHRP-6 regulatory status

Current status of GHRP-6 in the United States: Not eligible for compounding. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of GHRP-6?

Regulatory: Not eligible for compoundingWADA: WADA prohibitedVerified: Verified Sep 22, 2026
FDA and compounding
Not FDA approved for any use. FDA added GHRP-6 to the 503B Category 2 list on September 29, 2023, citing immunogenicity risk from aggregation and impurities, effects on cortisol, and increased blood glucose from reduced insulin sensitivity. As of the FDA page current to April 22, 2026, GHRP-6 remains in 503B Category 2 and has no 503A nomination, so no licensed pharmacy has a lawful basis to compound it. It was not among the peptides withdrawn from Category 2 in April 2026.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date.
  2. Not available as an FDA approved product; FDA placed GHRP-6 in 503B Category 2 on September 29, 2023 and it has no 503A nomination or listing.
  3. Products labeled research use only are not lawful for human use and are not verified for identity or purity.

Full GHRP-6 page: evidence, dosing in the literature, and sources

How has the status of GHRP-6 changed over time?

  1. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

    Source: WADA 2027 Prohibited List
  2. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

    Source: WADA Prohibited List
  3. WADA

    WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

    The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 (TB-500), and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

    Source: WADA Prohibited List
  4. FDA

    FDA places GHRP-2, GHRP-6, and ipamorelin in 503B Category 2

    On September 29, 2023 FDA added growth hormone releasing peptide-2 (GHRP-2, for injectable and nasal routes), GHRP-6, and ipamorelin acetate to Category 2 under the 503B interim policy, citing immunogenicity risk from aggregation and peptide related impurities and, for GHRP-2, reports of serious adverse events. Outsourcing facilities may not compound a substance while it is in 503B Category 2. All three remain listed on the FDA page current as of April 22, 2026.

    Regulatory: Not eligible for compoundingSource: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for GHRP-6 and the source of each dated event.

  1. [1]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  2. [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  3. [3]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimeticsWADA, 2026
  4. [4]WADA 2027 Prohibited ListWADA, 2026